Hunter Malanson News Today

01.21.21 -- Using Production And Postmarket Data To Validate FMEA Assumptions   Acepodias Dr. Sony Hsiao, CEO, and Dr. Mark Gilbert, SVP of R&D, join Business of Biotech for a discussion on the companys approach to dramatically reducing the cost of cell therapy development, manufacturing, and administration via its oNK, CAR, and ACC candidates. Listen now and subscribe so you never miss an episode. Featured Editorial By Mark Durivage, Quality Systems Complian...

Upstream Considerations For Biosimilar Development By Hunter Malanson, Staff Scientist, Field Applications; Mariana Curcio, Technical Sales Specialist; and Albert Cheong, Associate Director, Services & Product Application, Thermo Fisher Scientific Bioproduction Cell Culture Many of the early and costly steps of drug development can be eliminated with biosimilars, which offer several advantages to pharmaceutical companies exploring new strategies for increasing their presence in the market. Howe...